Cross-Sector entity
regulation is the sole category represented across all 2 tracked stories. Dr. Luli Akinfiresoye is most often covered alongside Duane Boise, which appears in 2 of these 2 stories. That works out to roughly 0.9 stories per week across a 15-day span.
2 verified stories tracked
Last mentioned: Aug 10, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 50 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 2 tracked stories. Dr. Luli Akinfiresoye is most often covered alongside Duane Boise, which appears in 2 of these 2 stories. That works out to roughly 0.9 stories per week across a 15-day span. We currently track 2 Cross-Sector stories that mention Dr. Luli Akinfiresoye, published between July 27, 2026 and August 10, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Dr. Luli Akinfiresoye. Shared-story counts are live from our verified record — not editorial picks.
Post-Hearing Briefs Due
Parties submit final briefs to Administrative Law Judge Derek C. Julius, summarizing their arguments on the evidentiary record and legal standards. The recommendation on rescheduling is expected to follow shortly thereafter.
Rescheduling Hearing Testimony
Under subpoena, Dr. Akinfiresoye testifies in the marijuana rescheduling proceeding that marijuana fails the first three factors of the DEA's five-factor test, directly contradicting the HHS Schedule III recommendation.
DEA Scientific Data Review Published
Dr. Luli Akinfiresoye authors the DEA's internal Scientific Data Review on marijuana, reportedly concluding that marijuana lacks sufficient, reproducible scientific evidence for accepted medical use.
ALJ Julius's upcoming recommendation in the DEA marijuana rescheduling hearing may challenge the government's novel approach of limiting Schedule III status to state-licensed medical programs, after DEA scientist testimony cast doubt on whether such programs satisfy the Controlled Substances Act's rigorous medical-use standard.
Source: nashvilleherald.com · pittsburghstar.com
DEA pharmacologist Dr. Luli Akinfiresoye testified that marijuana fails the agency's historical scientific standard for accepted medical use, directly contradicting the HHS recommendation to reschedule. This intra-agency conflict exposes the proposed Schedule III rule to a likely arbitrary-and-capricious challenge, redefining the evidentiary landscape for controlled substance rulemaking.
Source: newjerseytelegraph.com · pr-inside.com
